Search
forResearch 10 of 1000+
- Cutaneous manifestations associated with immune checkpoint inhibitors
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Revisión sistemática de los efectos adversos cutáneos causados por fármacos inhibidores de los puntos de control inmunitario: características, manejo y pronóstico
- [Translated article] Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review
- IMMUNE-RELATED SKIN TOXICITIES TO CHECKPOINT INHIBITORS THERAPY
- Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma
- Cutaneous lupus erythematosus induced by tislelizumab
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
- Cutaneous toxicities of new treatments for melanoma
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →